Abstract
At JADPRO Live 2025, Kevin Y. Chen, PharmD, MS, BCOP, CPP, reviewed therapeutic advances in solid tumors with an emphasis on newly approved targeted therapies and antibody–drug conjugates (ADCs). The session underscored the expanding role of biomarker-driven treatment selection and comprehensive molecular profiling. Dr. Chen also emphasized the role of oncology advanced practitioners in monitoring patients and managing toxicities of these agents in order to optimize outcomes.
References
Ahn, M.-J., Lisberg, A., Goto, Y., Sands, J., Hong, M. H., Paz-Ares, L., Pons-Tostivint, E., Pérol, M., Felip, E., Sugawara, S., Hayashi, H., Cho, B. C., Blumenschein, G., Jr., Shum, E., Lee, J.-S., Heist, R. S., Cornelissen, R., Chang, W.-C., Kowalski, D., Zebger-Gong, H., Chargualaf, M., Gu, W., Lan, L., Howarth, P., Joseph, R., & Okamoto, I. (2025). A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC. Journal of Thoracic Oncology, 20(11), 1669–1682. https://doi.org/10.1016/j.jtho.2025.06.002
Arrillaga-Romany, I., Gardner, S. L., Odia, Y., Aguilera, D., Allen, J. E., Batchelor, T., Butowski, N., Chen, C., Cloughesy, T., Cluster, A., de Groot, J., Dixit, K. S., Graber, J. J., Haggiagi, A. M., Harrison, R. A., Kheradpour, A., Kilburn, L. B., Kurz, S. C., Lu, G., MacDonald, T. J.,…Wen, P. Y. (2024). ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma. Journal of Clinical Oncology, 42(13), 1542–1552. https://doi.org/10.1200/JCO.23.01134
Banerjee, S. N., Van Nieuwenhuysen, E., Aghajanian, C., D’Hondt, V., Monk, B. J., Clamp, A., Prendergast, E., Oaknin, A., Ring, K., Colombo, N., Holloway, R. W., Rodrigues, M., Chon, H. S., Gourley, C., Santin, A. D., Thaker, P. H., Gennigens, C., Newman, G., Salinas, E., Youssoufian, H.,…Grisham, R. N. (2025). Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. Journal of Clinical Oncology, 43(25), 2782–2792. https://doi.org/10.1200/JCO-25-00112
Bardia, A., Jhaveri, K., Im, S. A., Pernas, S., De Laurentiis, M., Wang, S., Martínez Jañez, N., Borges, G., Cescon, D. W., Hattori, M., Lu, Y. S., Hamilton, E., Zhang, Q., Tsurutani, J., Kalinsky, K., Rubini Liedke, P. E., Xu, L., Fairhurst, R. M., Khan, S., Denduluri, N.,…TROPION-Breast01 Investigators (2025). Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. Journal of Clinical Oncology, 43(3), 285–296. https://doi.org/10.1200/JCO.24.00920
Camidge, D. R., Bar, J., Horinouchi, H., Goldman, J., Moiseenko, F., Filippova, E., Cicin, I., Ciuleanu, T., Daaboul, N., Liu, C., Bradbury, P., Moskovitz, M., Katgi, N., Tomasini, P., Zer, A., Girard, N., Cuppens, K., Han, J. Y., Wu, S. Y., Baijal, S.,…Lu, S. (2024). Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial. Journal of Clinical Oncology, 42(25), 3000–3011. https://doi.org/10.1200/JCO.24.00720
Drilon, A., Duruisseaux, M., Han, J.-Y., et al. (2021). Clinicopathologic features and response to therapy of NRG1 fusion–driven lung cancers: The eNRGy1 Global Multicenter Registry. Journal of Clinical Oncology, 39(25), 2791–2802. https://doi.org/10.1200/JCO.20.03307
Grisham, R. N., Aghajanian, C., Van Nieuwenhuysen, E., Rodrigues, M., Ring, K. L., Santin, A. D., Colombo, N., Prendergast, E. N., Thaker, P. H., Moore, K. N., Salinas, E. A., Ray-Coquard, I., Chon, H. S., Rose, P. G., Oaknin, A., Clamp, A. R., Gandhi, M. D., Monk, B. J., Holloway, R. W.,…Banerjee, S. N. (2023). Efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy: An analysis from ENGOT-ov60/GOG-3052/RAMP 201 (Abstract 1515) [Meeting abstract].
Heymach, J. V., Ruiter, G., Ahn, M. J., Girard, N., Smit, E. F., Planchard, D., Wu, Y. L., Cho, B. C., Yamamoto, N., Sabari, J. K., Zhao, Y., Tu, H. Y., Yoh, K., Nadal, E., Sadrolhefazi, B., Rohrbacher, M., von Wangenheim, U., Eigenbrod-Giese, S., Zugazagoitia, J., & Beamion LUNG-1 Investigators (2025). Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 392(23), 2321–2333. https://doi.org/10.1056/NEJMoa2503704
Laskin, J., Liu, S. V., Tolba, K., Heining, C., Schlenk, R. F., Cheema, P., Cadranel, J., Jones, M. R., Drilon, A., Cseh, A., Gyorffy, S., Solca, F., & Duruisseaux, M. (2020). NRG1 fusion-driven tumors: Biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents. Annals of Oncology, 31(12), 1693–1703. https://doi.org/10.1016/j.annonc.2020.08.2335
Merus N. V. (2025). Bizengri (zenocutuzumab) package insert. https://bizengri.com/pdf/BIZENGRI_Full_Prescribing_Information_2025.pdf
Pérol, M., Li, W., Pennell, N. A., Liu, G., Ohe, Y., De Braud, F., Nagasaka, M., Felip, E., Xiong, A., Zhang, Y., Fan, H., Wang, X., Li, S., Lai, R. K., Ran, F., Zhang, X., Chen, W., Bazhenova, L., & Zhou, C. (2025). Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST. Journal of Clinical Oncology, 43(16), 1920–1929. https://doi.org/10.1200/JCO-25-00275
